Abstract

Background

Our previous studies suggest that human fat extract (FE) contains a variety of angiogenic factors and may provide an alternative treatment option for stroke. However, the therapeutic effect is largely limited due to its short half-life, and inaccurate targeting.

Results

Herein, we leverage the targeting abilities of platelets (PLTs) to the lesion area of stroke and Arg-Gly-Asp (RGD) peptides to the angiogenic blood vessels to develop a biomimetic nanocarrier that capable of delivering FE precisely to treat stroke. The biomimetic nanocarriers are comprised of FE-encapsulated PLGA (poly(lactic-co-glycolic acid)) core enclosed by RGD peptides decorated plasma membrane of PLTs, namely RGD-PLT@PLGA-FE. We found that RGD-PLT@PLGA-FE not only targeted damaged and inflamed blood vessels but also achieved rapid accumulation in the lesion area of ischemic brain. In addition, RGD-PLT@PLGA-FE kept a sustained release behavior of FE at the lesion site, effectively increased its half-life and promoted angiogenesis and neurogenesis with delivering neurotrophic factors including BDNF, GDNF and bFGF to the brain, that ultimately resulted in blood flow increase and neurobehavioral recovery.

Conclusions

In conclusion, our study provides a new strategy to design a biomimetic system for FE delivery and it is a promising modality for stroke therapy.

Details

Title
Targeted delivery of fat extract by platelet membrane-cloaked nanocarriers for the treatment of ischemic stroke
Author
Wang, Cheng; Yang, Xuewei; Jiang, Yixu; Lin, Qi; Zhuge, Deli; Xu, Tongtong; Guo, Yiyan; Deng, Mingwu; Zhang, Wenjie; Tian, Dongyan; Yin, Qingqing; Li, Li; Zhang, Zhijun; Wang, Yongting; Guo-Yuan, Yang; Chen, Yijie; Tang, Yaohui  VIAFID ORCID Logo 
Pages
1-20
Section
Research
Publication year
2022
Publication date
2022
Publisher
BioMed Central
e-ISSN
14773155
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2678202410
Copyright
© 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.